{"id":"W4376133764","doi":"10.3324/haematol.2022.282411","title":"Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial","year":2023,"lang":"en","type":"article","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of British Columbia","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health; F. Hoffmann-La Roche","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Oncology; Internal medicine; Clinical trial; Stage (stratigraphy); Phases of clinical research; Pharmacology; Bone marrow; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00155453,0.00109779,0.001835889,0.0003238932,0.0003397885,0.0009488667,0.0006464189,0.001045647,0.002207431],"category_scores_gemma":[0.0008851683,0.0004617002,0.001125138,0.0002437306,0.0006329709,0.000709498,0.0002241623,0.002423586,0.000672431],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007270253,"about_ca_system_score_gemma":0.000803369,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005154985,"about_ca_topic_score_gemma":0.001314448,"domain_scores_codex":[0.9995615,0.0001944598,0.00002674502,0.00007667382,0.00004204445,0.00009864313],"domain_scores_gemma":[0.9995193,0.00008011319,0.0001030729,0.00003623469,0.00003263473,0.0002286312],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8421683,0.03095911,0.005401569,0.000435337,0.001119911,0.0001842793,0.0002378279,0.001547766,0.04211856,0.0001803213,0.003103646,0.07254353],"study_design_scores_gemma":[0.6182466,0.3593827,0.01368757,0.00003912089,0.0005555258,0.0002718586,0.00004652912,0.001377144,0.004415264,0.0001527511,0.001792802,0.00003214709],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995339,0.001586967,0.0002793324,0.0002826738,0.00005982473,0.0007709738,0.0005268758,0.00004952187,0.001104752],"genre_scores_gemma":[0.9949189,0.0009235829,0.0005370678,0.0003625958,0.00009976046,0.0009018251,0.001143605,0.00001680844,0.001095755],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002207431,"threshold_uncertainty_score":0.008221269,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03954079516253714,"score_gpt":0.3407638817034743,"score_spread":0.3012230865409371,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}